English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background and purpose  There is still no curative treatment for multiple sclerosis ( MS ), but during the last 20 years eight different disease‐modifying compounds have been approved for relapsing−remitting  MS  ( RRMS ).    Methods  A literature search was conducted on published randomized controlled phase III trials indexed in PubMed on the approved medications until 21 May 2015.    Results  In this review the mode of action, documented treatment effects and side effects of the approved  MS  therapies are briefly discussed.    Conclusions  Based on current knowledge of risk−benefit of the approved  MS  medications, including factors influencing adherence, it is suggested that oral treatment with dimethyl fumarate or teriflunomide should be preferred as a starting therapy amongst the first‐line preparations for  de novo   RRMS . In the case of breakthrough disease on first‐line therapy, or rapidly evolving severe  RRMS , second‐line therapy with natalizumab, fingolimod or alemtuzumab should be chosen based on careful risk−benefit stratification.

Disease‐modifying treatments for multiple sclerosis – a review of approved medications